Surena F Matin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7965233/publications.pdf

Version: 2024-02-01

227 papers

11,772 citations

57681 46 h-index 102 g-index

233 all docs 233 docs citations

233 times ranked 8673 citing authors

#	Article	IF	CITATIONS
1	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. European Urology Focus, 2022, 8, 491-497.	1.6	13
2	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International, 2022, 129, 610-620.	1.3	22
3	Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: ⟨i⟩post hoc⟨li⟩ analysis from Eastern Cooperative Oncology Groupâ€American College of Radiology Imaging Network (ECOGâ€ACRIN) E2805. BJU International, 2022, 129, 718-722.	1.3	1
4	Multimodal kidneyâ€preserving approach in localised and locally advanced highâ€risk upper tract urothelial carcinoma. BJUI Compass, 2022, 3, 37-44.	0.7	3
5	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000235002.	0.2	1
6	Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clinical Genitourinary Cancer, 2022, , .	0.9	3
7	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000245402.	0.2	1
8	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 176-182.	0.9	5
9	Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. Journal of Urology, 2022, 207, 779-788.	0.2	29
10	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU International, 2021, 127, 528-537.	1.3	10
11	Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. European Urology Focus, 2021, 7, 397-403.	1.6	12
12	Impact of upper tract urothelial carcinoma on response to BCG in patients with nonâ€muscleâ€invasive bladder cancer. BJU International, 2021, 128, 568-574.	1.3	2
13	Editorial Comment. Journal of Urology, 2021, 205, 1046-1046.	0.2	O
14	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. European Urology Oncology, 2021, 4, 170-179.	2.6	28
15	Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. American Journal of Roentgenology, 2021, 217, 1-7.	1.0	1
16	Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Translational Andrology and Urology, 2021, 10, 2233-2245.	0.6	6
17	Longâ€term renal functional outcomes following ureteroureterostomy performed during multiâ€organ resection for nonâ€urothelial cancers. BJUI Compass, 2021, 2, 348-354.	0.7	2
18	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e17-790.e23.	0.8	3

#	Article	IF	CITATIONS
19	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e15-788.e21.	0.8	2
20	The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Journal of Urology, 2021, 206, 558-567.	0.2	27
21	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology, 2021, 206, 548-557.	0.2	9
22	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology, 2021, 155, 144-151.	0.5	2
23	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e9-837.e17.	0.8	3
24	Editorial Comment. Journal of Urology, 2021, 206, 576-576.	0.2	0
25	Reply by Authors. Journal of Urology, 2021, 206, 567-567.	0.2	0
26	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. European Urology, 2021, 80, 507-515.	0.9	27
27	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021, 12, 6375.	5.8	22
28	Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU International, 2021, , .	1.3	0
29	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. European Urology Focus, 2020, 6, 104-111.	1.6	18
30	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851.	15.2	193
31	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. European Urology Open Science, 2020, 19, 16-19.	0.2	2
32	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1780-1785.	0.6	8
33	Incidence and preoperative predictors for major complications following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1786-1793.	0.6	10
34	Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer, 2020, 126, 3950-3960.	2.0	34
35	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 933.e7-933.e12.	0.8	10
36	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European Urology, 2020, 78, 209-220.	0.9	66

#	Article	IF	Citations
37	UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093795.	1.4	7
38	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 737.e11-737.e16.	0.8	10
39	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU International, 2020, 126, 745-753.	1.3	20
40	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncology, The, 2020, 21, 776-785.	5.1	82
41	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2020, 203, 690-698.	0.2	76
42	Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. Journal of Urology, 2020, 203, 1101-1108.	0.2	36
43	Ablation of Renal Cell Carcinoma. , 2020, , 823-835.e4.		O
44	Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors. Journal of Kidney Cancer and VHL, 2020, 7, 1-5.	0.2	4
45	Reply by Authors. Journal of Urology, 2020, 203, 697-698.	0.2	O
46	Conditional survival of patients with small renal masses undergoing active surveillance. BJU International, 2019, 123, 447-455.	1.3	14
47	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 758-764.	0.8	21
48	Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Modern Pathology, 2019, 32, 1698-1707.	2.9	35
49	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	5 . 8	140
50	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 354.e19-354.e26.	0.8	4
51	EDITORIAL COMMENT. Urology, 2019, 132, 74.	0.5	O
52	Lynch syndrome and urologic malignancies. Current Opinion in Urology, 2019, 29, 357-363.	0.9	26
53	Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 292.e1-292.e9.	0.8	34
54	Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean―using routine clinical features with correlating biochemical relapse rates. Asian Journal of Andrology, 2019, 21, 598.	0.8	11

#	Article	IF	CITATIONS
55	Surgeonâ€led prostate cancer lymph node staging: pathological outcomes stratified by robotâ€assisted dissection templates and patient selection. BJU International, 2018, 122, 66-75.	1.3	10
56	Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World Journal of Urology, 2018, 36, 1093-1101.	1.2	36
57	Endoscopic Approaches to Upper Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 267-286.	0.8	23
58	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2018, 115, 119-124.	0.5	19
59	Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JAMA Oncology, 2018, 4, 1010.	3.4	4
60	Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis, 2018, 39, 752-757.	1.3	18
61	Re: Association Between Lymph Node Yield and Survival Among Patients Undergoing Radical Nephroureterectomy for Urothelial Carcinoma of the Upper Tract. European Urology, 2018, 73, 811-812.	0.9	0
62	Editorial Comment. Journal of Urology, 2018, 199, 938-939.	0.2	1
63	Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial. Diseases of the Colon and Rectum, 2018, 61, 77-83.	0.7	28
64	Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology, 2018, 116, 114-119.	0.5	19
65	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliative and Supportive Care, 2018, 16, 146-154.	0.6	5
66	Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. Journal of Urology, 2018, 199, 393-400.	0.2	70
67	A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e19-13.e25.	0.8	6
68	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	1.3	22
69	Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. Journal of Urology, 2018, 199, 60-65.	0.2	54
70	Radical Nephrectomy is the Treatment of Choice for Complex, Localized Renal Tumors. Kidney Cancer, 2018, 2, 5-9.	0.2	0
71	Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer, 2018, 124, 4023-4031.	2.0	30
72	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1351-1359.	5.1	63

#	Article	IF	Citations
73	Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence. American Journal of Pathology, 2018, 188, 2487-2496.	1.9	34
74	Salvage topical therapy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 2027-2034.	1.2	11
75	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2018, 36, 1973-1980.	1.2	10
76	Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. Journal of Endourology, 2018, 32, 806-811.	1.1	6
77	The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urology and Nephrology, 2018, 70, 109-125.	1.3	4
78	Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome. Bladder Cancer, 2018, 4, 261-268.	0.2	28
79	Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget, 2018, 9, 23390-23395.	0.8	15
80	Systemic Chemotherapy for Upper Tract Urothelial Cancer. , 2018, , 315-321.		0
81	Upper Urinary Tract Carcinoma In Situ. , 2018, , 85-95.		0
82	Endoluminal Ultrasound for Upper Tract Urothelial Carcinoma. , 2018, , 63-70.		0
83	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World Journal of Urology, 2017, 35, 355-365.	1.2	39
84	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	1.2	26
85	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psycho-Oncology, 2017, 26, 1361-1368.	1.0	22
86	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer, 2017, 15, 363-370.	0.9	17
87	Editorial Comment. Urology, 2017, 100, 150.	0.5	0
88	Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. Journal of Urology, 2017, 198, 281-288.	0.2	47
89	Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. European Urology, 2017, 71, 987.	0.9	1
90	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. Journal of Urology, 2017, 198, 530-537.	0.2	55

#	Article	IF	Citations
91	Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2017, 72, 641-649.	0.9	170
92	Optimizing management of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 492-498.	0.8	18
93	Prognostic significance of promoter CpG island methylation of obesityâ€related genes in patients with nonmetastatic renal cell carcinoma. Cancer, 2017, 123, 3617-3627.	2.0	25
94	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. Journal of Endourology, 2017, 31, 946-953.	1.1	33
95	Editorial Comment. Journal of Urology, 2017, 198, 551-551.	0.2	0
96	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Research, 2017, 77, 5313-5326.	0.4	19
97	Multiple Renal Artery Pseudoaneurysms in Patients Undergoing Renal Artery Embolization Following Partial Nephrectomy: Correlation with RENAL Nephrometry Scores. CardioVascular and Interventional Radiology, 2017, 40, 202-209.	0.9	8
98	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. Journal of Urology, 2017, 197, 287-295.	0.2	43
99	Cryoablation for cT1b Renal Tumors? Yet To Be Determined. European Urology, 2017, 71, 118-119.	0.9	2
100	Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal. Minerva Urology and Nephrology, 2016, 69, 38-55.	1.3	12
101	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. Journal of Urology, 2016, 196, 678-684.	0.2	24
102	Predicting and Determining the Success of Percutaneous Ablation. Journal of Urology, 2016, 196, 7-8.	0.2	0
103	Tribute to Dr. David Swanson. Urology, 2016, 95, 1.	0.5	0
104	Geneâ€environment interaction of genomeâ€wide association studyâ€identified susceptibility loci and meatâ€cooking mutagens in the etiology of renal cell carcinoma. Cancer, 2016, 122, 108-115.	2.0	24
105	Quality-of-life outcomes in patients with small renal masses. Nature Reviews Urology, 2016, 13, 443-444.	1.9	2
106	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	1.3	27
107	Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU International, 2016, 117, 775-782.	1.3	65
108	Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischargeâ€, Journal of Surgical Research, 2016, 202, 196-203.	0.8	20

#	Article	IF	CITATIONS
109	Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. Journal of Urology, 2016, 195, 241-242.	0.2	0
110	Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case–Control Study. Clinical Cancer Research, 2016, 22, 2074-2082.	3.2	22
111	Comparison of Single-docking Robotic-assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection During Nephroureterectomy With Bladder Cuff Excision for Upper-tract Urothelial Carcinoma. Urology, 2016, 87, 216-223.	0.5	28
112	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 2016, 69, 866-874.	0.9	272
113	Contemporary Evaluation and Management of Upper Tract Urothelial Cancer. Urology, 2016, 94, 17-23.	0.5	10
114	Author Reply. Urology, 2016, 87, 222-223.	0.5	0
115	Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clinical Genitourinary Cancer, 2016, 14, 130-138.	0.9	14
116	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq0 0 0 rgB1	「/Qyerlock	2 10 Tf 50 46
117	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 237.e19-237.e26.	0.8	13
118	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na \tilde{A}^- ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. European Urology, 2016, 69, 855-862.	0.9	228
119	Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. European Urology, 2016, 69, 116-128.	0.9	103
120	Mitomycin-C induction and maintenance topical therapy for upper tract urothelial carcinoma. Journal of Clinical Oncology, 2016, 34, 411-411.	0.8	1
121	Upper tract urothelial carcinoma: epidemiology, high risk populations and detection. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2016, 68, 350-8.	3.9	12
122	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 427.e17-427.e23.	0.8	35
123	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. Journal of Urology, 2015, 194, 21-29.	0.2	66
124	Surgical considerations for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 528-537.	0.8	23
125	Implementation of a Very Low Calorie Diet in Patients UndergoingÂUrologic Surgery: Room for Improvement?. Clinical Genitourinary Cancer, 2015, 13, e203-e204.	0.9	O
126	Salvage surgery after energy ablation for renal masses. BJU International, 2015, 115, 74-80.	1.3	24

#	Article	IF	Citations
127	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psycho-Oncology, 2015, 24, 1477-1484.	1.0	23
128	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029.	1.6	159
129	Safety and diagnostic accuracy of percutaneous biopsy in upper tract urothelial carcinoma. BJU International, 2015, 115, 625-632.	1.3	22
130	Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology, 2015, 86, 10-15.	0.5	21
131	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 166.e21-166.e29.	0.8	44
132	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 53-64.	0.8	11
133	Preoperative Predictors of Pathological Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing Retroperitoneal Lymph Node Dissection. Journal of Urology, 2015, 193, 1101-1107.	0.2	43
134	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology, 2015, 194, 316-322.	0.2	49
135	Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. Journal of Urology, 2015, 194, 1567-1574.	0.2	69
136	Bridging the Gap in Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 978-979.	0.9	4
137	Re: A Randomized Trial of Robot-assisted Laparoscopic Radical Cystectomy. European Urology, 2015, 67, 173-174.	0.9	1
138	Mucinous tubular and spindle cell carcinoma (<scp>MTSCC</scp>) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU International, 2015, 116, 85-92.	1.3	44
139	Endoluminal Ultrasonography. , 2015, , 131-138.		0
140	Thermal Ablative Techniques in Renal Cell Carcinoma. , 2015, , 195-215.		0
141	â€~Discontent is the first necessity of progress', <scp>T</scp> homas <scp>A</scp> . <scp>E</scp> dison. BJU International, 2014, 114, 635-635.	1.3	0
142	Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. Journal of Urology, 2014, 192, 36-42.	0.2	12
143	Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World Journal of Urology, 2014, 32, 265-271.	1.2	34
144	Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndromeâ€"clinicopathological features and comparative genomic analysis of 3 cases. Human Pathology, 2014, 45, 1966-1972.	1.1	31

#	Article	IF	Citations
145	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014, 120, 1794-1799.	2.0	154
146	Early Experience of Robotic-Assisted Inguinal Lymphadenectomy: Review of Surgical Outcomes Relative to Alternative Approaches. Current Urology Reports, 2014, 15, 412.	1.0	27
147	Highlights from the first symposium on upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 309-316.	0.8	15
148	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 65, 210-217.	0.9	201
149	Technical challenges in 3 T magnetic resonance spectroscopic imaging of the prostate-A single-institution experience. Quantitative Imaging in Medicine and Surgery, 2014, 4, 251-8.	1.1	2
150	Correlation of histomorphologic findings and partial neurovascular bundle preservation during laparoscopic and robotic radical prostatectomy. Journal of Robotic Surgery, 2013, 7, 1-8.	1.0	2
151	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. Journal of Urology, 2013, 189, 1214-1221.	0.2	291
152	Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. European Urology, 2013, 63, 1122-1127.	0.9	88
153	Editorial Comment. Urology, 2013, 82, 268-269.	0.5	2
154	889 SURVIVAL OUTCOMES IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY FOR UPPER TRACT UROTHELIAL CELL CARCINOMA. Journal of Urology, 2013, 189, .	0.2	1
155	Re: Pilot Trial of Sunitinib Therapy in Patients with von Hippel-Lindau Disease. European Urology, 2013, 63, 770.	0.9	1
156	Thermal Ablation. , 2013, , 155-166.		0
157	Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU International, 2013, 111, 997-1005.	1.3	22
158	Phase 1 prospective evaluation of the oncological adequacy of robotic assisted videoâ€endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU International, 2013, 111, 1068-1074.	1.3	66
159	Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide highâ€volume centre in <scp>C</scp> hina. BJU International, 2013, 112, 917-924.	1.3	63
160	Accepting the positive results of unconventional methods. BJU International, 2013, 112, 5-6.	1.3	0
161	Real-Time Magnetic Resonance Imaging–Guided Cryoablation of Small Renal Tumors at 1.5 T. Investigative Radiology, 2013, 48, 437-444.	3.5	40
162	Perioperative chemotherapy for upper tract urothelial cancer. Nature Reviews Urology, 2012, 9, 266-273.	1.9	18

#	Article	IF	CITATIONS
163	Comprehensive Assessment of Quality of Life and Psychosocial Adjustment in Patients With Renal Tumors Undergoing Open, Laparoscopic and Nephron Sparing Surgery. Journal of Urology, 2012, 187, 822-826.	0.2	34
164	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 821-824.	0.8	33
165	Editorial Comment. Journal of Urology, 2012, 188, 2211-2211.	0.2	2
166	Editorial Comment. Urology, 2012, 79, 845.	0.5	0
167	Renal Tumors. , 2012, , 287-309.		0
168	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 2012, 62, 100-114.	0.9	349
169	Benign Renal Tumors. , 2012, , 1492-1505.e5.		3
170	Energy Ablative Techniques in Renal Cell Carcinoma. , 2012, , 141-161.		0
171	Chyluria After Radiofrequency Ablation of Renal Tumors. Journal of Vascular and Interventional Radiology, 2011, 22, 924-927.	0.2	12
172	Ablation of Kidney Tumors. Surgical Oncology Clinics of North America, 2011, 20, 341-353.	0.6	12
173	Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy. Urology, 2011, 78, 61-67.	0.5	43
174	Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. European Urology, 2011, 60, 1273-1279.	0.9	69
175	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2011, 59, 10-15.	0.9	98
176	High-Frequency Endoluminal Ultrasonography as an Aid to the Staging of Upper Tract Urothelial Carcinoma. Journal of Ultrasound in Medicine, 2010, 29, 1277-1284.	0.8	33
177	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer, 2010, 116, 3378-3388.	2.0	183
178	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for highâ€risk upper tract transitional cell carcinoma. Cancer, 2010, 116, 3127-3134.	2.0	208
179	Renal functional outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU International, 2010, 105, 496-500.	1.3	74
180	Laparoscopy-Assisted Radical Nephrectomy with Inferior Vena Caval Thrombectomy for Level II to III Tumor Thrombus: A Single-Institution Experience and Review of the Literature. Journal of Endourology, 2010, 24, 1005-1012.	1.1	39

#	Article	IF	Citations
181	Radio Frequency Ablation of Renal Tumors in Patients With Metastatic Renal Cell Carcinoma. Journal of Urology, 2010, 184, 1882-1887.	0.2	5
182	Immunological Response to Renal Cryoablation in an In Vivo Orthotopic Renal Cell Carcinoma Murine Model. Journal of Urology, 2010, 183, 333-338.	0.2	36
183	Characterization of Contrast Enhancement in the Ablation Zone Immediately after Radiofrequency Ablation of Renal Tumors. Journal of Vascular and Interventional Radiology, 2010, 21, 690-695.	0.2	31
184	Determining Failure After Renal Ablative Therapy for Renal Cell Carcinoma: False-negative and False-positive Imaging Findings. Urology, 2010, 75, 1254-1257.	0.5	15
185	Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. Journal of Urology, 2010, 183, 929-934.	0.2	84
186	Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 801-807.	1.1	91
187	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009, 115, 1224-1233.	2.0	943
188	Office Cystoscopy and Transrectal Ultrasound-guided Prostate Biopsies Pose Minimal Risk: Prospective Evaluation of 921 Procedures. Urology, 2009, 73, 1175-1178.	0.5	6
189	Guideline for Management of the Clinical T1 Renal Mass. Journal of Urology, 2009, 182, 1271-1279.	0.2	1,697
190	Laparoscopic Ultrasonography. , 2009, , 7-15.		1
191	Outcomes of laparoscopic partial nephrectomy after fellowship training. Journal of the Society of Laparoendoscopic Surgeons, 2009, 13, 154-9.	0.5	7
192	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Current Oncology Reports, 2008, 10, 253-258.	1.8	9
193	Patterns of intervention for renal lesions in von Hippelâ€Lindau disease. BJU International, 2008, 102, 940-945.	1.3	32
194	Contemporary strategies for treating nonhereditary synchronous bilateral renal tumors and the impact of minimally invasive, nephron-sparing techniques. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 37-42.	0.8	9
195	Comparing Lymphadenectomy During Radical Nephroureterectomy: Open Versus Laparoscopic. Urology, 2008, 71, 413-416.	0.5	36
196	A Pilot Trial of Vascular Targeted Photodynamic Therapy for Renal Tissue. Journal of Urology, 2008, 180, 338-342.	0.2	10
197	Surgical and Medical Treatment. , 2008, , 377-399.		0
198	Nephron-sparing probe ablative therapy: long-term outcomes. Current Opinion in Urology, 2008, 18, 150-156.	0.9	19

#	Article	IF	Citations
199	Laparoscopic radical nephroureterectomy for transitional cell carcinoma: where are we in 2007?. Current Opinion in Urology, 2007, 17, 83-87.	0.9	14
200	Is Radiofrequency Ablation Safe for Solitary Kidneys?. Urology, 2007, 69, 819-823.	0.5	41
201	Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Urology, 2007, 70, 252-256.	0.5	107
202	Laparoscopic Partial Nephrectomy: Experience in 60 Cases. Journal of Endourology, 2007, 21, 71-74.	1.1	13
203	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma With Nonclear Cell Histology. Journal of Urology, 2007, 178, 1896-1900.	0.2	62
204	Unexpected Atypical Findings on CT after Radiofrequency Ablation for Small Renal-cell Carcinoma and the Role of Percutaneous Biopsy. Journal of Vascular and Interventional Radiology, 2007, 18, 1186-1191.	0.2	31
205	Residual and Recurrent Disease Following Renal Energy Ablative Therapy: A Multi-Institutional Study. Journal of Urology, 2006, 176, 1973-1977.	0.2	185
206	Partial nephrectomy for renal urothelial tumors: Clinical update. Urology, 2006, 67, 490-495.	0.5	10
207	Recognition and preservation of accessory pudendal arteries during laparoscopic radical prostatectomy. Urology, 2006, 67, 1012-1015.	0.5	33
208	Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experience. Urology, 2006, 68, 528-532.	0.5	51
209	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?. BJU International, 2006, 98, 1176-1180.	1.3	116
210	Conventional and Hand-Assisted Laparoscopic Radical Nephrectomy: Comparative Analysis of 271 Cases. Journal of Endourology, 2006, 20, 891-894.	1.1	23
211	Percutaneous radiofrequency ablation: minimally invasive therapy for renal tumors. Expert Review of Anticancer Therapy, 2006, 6, 1735-1744.	1.1	13
212	Radical laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: current status. BJU International, 2005, 95, 68-74.	1.3	19
213	Percutaneous Transthoracic Radiofrequency Ablation of Renal Tumors Using an latrogenic Pneumothorax. American Journal of Roentgenology, 2005, 185, 86-88.	1.0	22
214	Percutaneous Radiofrequency Ablation of Renal Tumors: Technique, Complications, and Outcomes. Journal of Vascular and Interventional Radiology, 2005, 16, 679-688.	0.2	109
215	RECURRENCE AND SURVIVAL FOLLOWING LAPAROSCOPIC RADICAL NEPHROURETERECTOMY WITH VARIOUS FORMS OF BLADDER CUFF CONTROL. Journal of Urology, 2005, 173, 395-400.	0.2	158
216	PROSPECTIVE RANDOMIZED COMPARISON OF TRANSPERITONEAL VERSUS RETROPERITONEAL LAPAROSCOPIC RADICAL NEPHRECTOMY. Journal of Urology, 2005, 173, 38-41.	0.2	289

#	Article	IF	CITATIONS
217	Laparoscopic approaches to urologic malignancies. Current Treatment Options in Oncology, 2003, 4, 373-383.	1.3	12
218	Prospective randomized trial of skin adhesive versus sutures for closure of 217 laparoscopic Port-Site incisions. Journal of the American College of Surgeons, 2003, 196, 845-853.	0.2	50
219	Laparoscopic Radical Nephrectomy For Cancer With Level I Renal Vein Involvement. Journal of Urology, 2003, 169, 487-491.	0.2	112
220	Evaluation of Age and Comorbidity as Risk Factors After Laparoscopic Urological Surgery. Journal of Urology, 2003, 170, 1115-1120.	0.2	84
221	Comparative Analysis of Laparoscopic Versus Open Partial Nephrectomy for Renal Tumors in 200 Patients. Journal of Urology, 2003, 170, 64-68.	0.2	573
222	Modified Pfannenstiel incision for intact specimen extraction after retroperitoneoscopic renal surgery. Urology, 2003, 61, 830-832.	0.5	27
223	Laparoscopic Radical Cystectomy with Urinary Diversion: Completely Intracorporeal Technique. Journal of Endourology, 2002, 16, 335-341.	1.1	45
224	Laparoscopic radical nephrectomy: Retroperitoneal versus transperitoneal approach. Current Urology Reports, 2002, 3, 164-171.	1.0	25
225	Benign prostatic hyperplasia mimicking bladder tumor. Urology, 2001, 57, 1166.	0.5	2
226	Laparoscopic Ultrasonography. Journal of Endourology, 2001, 15, 87-92.	1.1	32
227	LAPAROSCOPIC MARSUPIALIZATION OF THE DIFFICULT LYMPHOCELE USING INTERNALIZED PERITONEAL DIALYSIS CATHETER. Journal of Urology, 2000, 163, 1498-1500.	0.2	10